A Study of Tocilizumab in Participants With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Non-Biological Disease-modifying Anti-rheumatic Drugs (DMARDs)

Non-interventional Local Study to Describe the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-biologic DMARD

This observational study will evaluate the safety and efficacy of tocilizumab in participants with active moderate to severe RA and an inadequate response to non-biologic DMARDs. Data will be collected from each eligible participant initiating tocilizumab treatment over 6 months.

Inclusion Criteria:

• Moderate to severe active RA (European League Against Rheumatism [EULAR] criteria)
• Inadequate response to DMARDs or tumor necrosis factor (TNF) antagonists
• Initiating treatment with tocilizumab according to SPC

Exclusion Criteria:

• Rheumatic autoimmune disease other than RA
• Prior history or current inflammatory joint disease other than RA
• Previous treatment with any biological drug used in the treatment of RA
• Previous treatment with tocilizumab
• Any contraindication to treatment with tocilizumab
• Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following enrollment
• Pregnant women or nursing (breastfeeding) mothers